For this purpose, we developed gelatin nanoparticles (GNP) which was surface modified with NeutrAvidin-biotinylated epidermal growth factor (bEGF) to facilitate EGFR-mediated endocytosis in tumor cells (NSCLC). The gene discussed is EGF; the disease is non-small cell lung carcinoma.